Distal symmetric polyneuropathy is the most common complication of diabetes, and a substantial subgroup of affected patients experience it as pain rather than numbness — burning, shooting, or electric sensations in the feet that typically worsen at night. Painful diabetic peripheral neuropathy (PDPN) is one of the harder problems in diabetes care: it is common, it degrades sleep and mood, and the treatments available reduce pain without altering the underlying nerve damage. The last decade has produced a clearer evidence base on which drugs to use, what to do when a single agent fails, and where device-based therapy fits.
How Common Is Diabetic Neuropathy, and How Often Is It Painful?
The American Diabetes Association position statement by Pop-Busui and colleagues (Diabetes Care, 2017) remains the reference document for scope and screening. Distal symmetric polyneuropathy affects at least 20% of people with type 1 diabetes after 20 years of disease, may already be present in 10–15% of newly diagnosed type 2 patients, and rises toward 50% after 10 years of type 2 disease. Critically, up to half of diabetic peripheral neuropathies are asymptomatic — which is why the statement emphasizes annual screening with simple bedside tools (10-g monofilament testing for protective sensation, plus a small-fiber and large-fiber assessment such as pinprick, temperature, and 128-Hz tuning fork vibration) rather than waiting for a patient to report symptoms.
First-Line Drug Therapy: What the AAN Guideline Recommends
The American Academy of Neurology updated its practice guideline on oral and topical treatment of painful diabetic polyneuropathy in Neurology in 2022 (Price and colleagues). After systematic review, the guideline concluded that four medication classes have comparable, moderate effect sizes and should be offered: tricyclic antidepressants, serotonin–norepinephrine reuptake inhibitors (such as duloxetine and venlafaxine), gabapentinoids (gabapentin and pregabalin), and sodium channel blockers (including oxcarbazepine and lamotrigine). Because no class clearly outperforms the others, selection is driven by comorbidities, side-effect profile, drug interactions, and cost.
Two further recommendations are worth emphasizing. First, the guideline advises clinicians not to use opioids for PDPN, citing an unfavourable balance of limited long-term efficacy against harms including dependence. Second, it directs clinicians to assess patients with PDPN for concurrent mood and sleep disorders, which are both common in this population and independently worsen the pain experience.
When One Medication Is Not Enough: The OPTION-DM Trial
A persistent gap in the evidence was which first-line pathway to choose, and what to add when monotherapy falls short. The OPTION-DM trial (Tesfaye and colleagues, The Lancet, 2022) addressed this directly. In this multicentre, double-blind, randomised crossover trial, patients cycled through three 16-week treatment pathways: amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin. Each pathway began with six weeks of monotherapy, and combination therapy was added only if pain relief remained suboptimal.
The three pathways produced similar analgesic efficacy — no clear winner among the monotherapies. However, adding a second agent in patients with inadequate response to monotherapy produced additional pain relief and was well tolerated. The practical message is that the choice of first drug matters less than a structured approach: adequate titration, adequate duration, and a willingness to combine agents rather than repeatedly switching.
Topical and Device-Based Options
For patients who cannot tolerate systemic drugs, the high-concentration capsaicin 8% patch is an alternative. Vinik and colleagues (BMC Neurology, 2016) reported a 52-week randomised open-label safety study of repeat patch treatment plus standard of care versus standard of care alone in PDPN, and found no worsening of sensory perception to sharp, warm, cold, or vibration stimuli by the end of the study — an important reassurance in a population already at risk of sensory loss.
At the refractory end of the spectrum, high-frequency spinal cord stimulation has accumulated substantial trial data. The SENZA-PDN randomised controlled trial compared conventional medical management alone against 10 kHz spinal cord stimulation plus conventional management in 216 patients with refractory PDPN. In the 24-month results reported by Petersen and colleagues (Diabetes Research and Clinical Practice, 2023), the 142 patients followed with an implanted system had a mean pain reduction of 79.9% from baseline, with 90.1% achieving at least 50% pain relief, alongside improvements in health-related quality of life and sleep. Notably, 65.7% demonstrated clinically meaningful neurological improvement on sensory, reflex, and motor testing. Five systems (3.2%) were explanted because of infection — a reminder that this is an invasive therapy with real, if uncommon, risk.
Pain Relief Is Not the Same as Protection
An important clinical distinction is that treating neuropathic pain does not restore protective sensation. Patients whose burning pain improves may still have an insensate foot and remain at risk of unnoticed trauma and ulceration. Symptom control and structural foot risk are assessed separately: the former by pain scores and functional measures, the latter by monofilament testing, vascular assessment, and inspection for deformity and callus.
Summary
Diabetic peripheral neuropathy is common and frequently silent, making systematic screening more reliable than symptom reporting. When pain is present, current guidance supports tricyclics, SNRIs, gabapentinoids, and sodium channel blockers as comparable first-line options, and advises against opioids. Randomised evidence supports combining agents when monotherapy is insufficient rather than cycling through single drugs. Topical capsaicin and, in refractory cases, 10 kHz spinal cord stimulation extend the range of options. Throughout, effective analgesia should not be mistaken for restored sensation.
References
- Pop-Busui R, Boulton AJM, Feldman EL, et al. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017.
- Price R, Smith AG, Franklin G, et al. Oral and Topical Treatment of Painful Diabetic Polyneuropathy: Practice Guideline Update Summary: Report of the AAN Guideline Subcommittee. Neurology. 2022.
- Tesfaye S, Sloan G, Petrie J, et al. Comparison of amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin for the treatment of diabetic peripheral neuropathic pain (OPTION-DM): a multicentre, double-blind, randomised crossover trial. The Lancet. 2022.
- Vinik AI, Perrot S, Vinik EJ, et al. Capsaicin 8% patch repeat treatment plus standard of care (SOC) versus SOC alone in painful diabetic peripheral neuropathy: a randomised, 52-week, open-label, safety study. BMC Neurology. 2016.
- Petersen EA, Stauss TG, Scowcroft JA, et al. Long-term efficacy of high-frequency (10 kHz) spinal cord stimulation for the treatment of painful diabetic neuropathy: 24-month results of a randomized controlled trial. Diabetes Research and Clinical Practice. 2023.
Comments
